Interleukin-6 human ELISA

Immunoenzymetric assay for the in vitro quantitative measurement of human interleukin-6 (IL-6) in serum.

INTENDED USE:Immunoenzymetric assay for the in vitro quantitative measurement of human interleukin-6 (IL-6) in serum.

GENERAL INFORMATION:

A. Biological activities
Human Interleukin 6 (IL-6) is a 184 A.A. polypeptide with potential O and N-glycosylation sites, and a significant homology with G-CSF. It is produced by various cells, including T- and B-cells, monocytes, fibroblasts, keratinocytes, endothelial cells, mesangial cells, astrocytes, bone marrow stroma cells and several tumor cells. It regulates the growth and differentiation of various cell types with major activities on the immune system, hematopoïesis, and inflammation. These multiple actions are integrated within a complex cytokine network, where several cytokines induce (IL-1, TNF, PDGF, IFNs,...) or are induced by IL-6 and the final effects result from either synergistic or antagonistic activities between IL-6 and the other cytokines (IL-1, IL-2, IL-4, IL-5,IFNγ, IL-3, GM-CSF, M-CSF,CSF,...). IL-6 induces final maturation of B-cells into antibody producing cells and is a potent growth factor for myeloma/plasmacytoma cells. It (co-) stimulates T-cell growth and cytotoxic T-cell differentiation. It promotes megakaryocyte development and synergizes with other cytokines to stimulate multipotent hematopoïetic progenitors. It can also induce differentiation and growth inhibition of some leukemia -or non hematopoïetic tumoral cell lines. IL-6 is also a major inducer of the acute phase reactions in response to inflammation or tissue injury. Along with IL-1 and TNF, it induces the synthesis of acute phase proteins (APP) by hepatocytes, each cytokine or combination of cytokines showing a preferential pattern of APP production. IL-6 also interacts with the neuroendocrine system, e.g. by inducing ACTH production. Thus, IL-6 is a pleiotropic cytokine with multiple endocrine, paracrine and possibly autocrine activities in various tissues.

B. Clinical application
Although most normal controls have undetectable levels of IL-6 in their serum, huge quantities of IL-6 are detected in severe inflammatory situations such as septicemia. The elevation of serum IL-6 precedes that of acute phase proteins, e.g. in a postoperative phenomenon, and may thus be a sensitive early parameter to investigate inflammatory conditions. Serum IL-6 has already been described in association with surgical or traumatic tissue injuries, infectious diseases, auto-immune diseases including arthritis, graft rejection, alcoholic liver cirrhosis, malignancies, etc.IV.

KIT CHARACTERISTICS:
- Method: ELISA
- Tests: 96
- Incubation Time / Conditions: 1 h, 1 h, 15 min (RT/shaker)
- Standard Range: 19.1 - 2,369 pg/ml
- Sensitivity analytical: 2 pg/ml
- Final Sample Volume: 100 µl
- Sample Type: serum
- Isotope / Substrate: TMB 450 nm
- Internal Controls: 2
- Regulatory Status: CE